

Data Item	NAACCR Item Number	Collection Dates
Abstractor Initials	570	1995 - present
Address at Dx City	70	1995 - present
Address at Dx State	80	1995 - present
Address at Dx Street Address	2330	1995 - present
Address at Dx Supplemental	2335	2006 - present
Address at Dx Zip Code	100	1995 - present
Address at Dx-Country	102	2013 - present
Date Regional Lymph Node Dissection	682	2022 – present
Adenopathy	3804	2022 - present
AJCC TNM Clin T	1001	2018 - present
AJCC TNM Clin N	1002	2018 - present
AJCC TNM Clin M	1003	2018 - present
AJCC TNM Clin Stage Group	1004	2018 - present
AJCC TNM Path T	1011	2018 - present
AJCC TNM Path N	1012	2018 - present
Age at Diagnosis	230	1995 - present
AJCC ID	995	2018 - present
AJCC TNM Path M	1013	2018 - present
AJCC TNM Path Stage Group	1014	2018 - present
AJCC TNM Post Therapy Path (yc) T	1021	2021 - present
AJCC TNM Post Therapy Path (yc) N	1022	2021 - present
AJCC TNM Post Therapy Path (yc) M	1023	2021 - present
AJCC TNM Post Therapy Path Stage Group	1024	2021 - present
AJCC TNM Clin T Suffix	1031	2021 - present
AJCC TNM Path T Suffix	1032	2021 - present
AJCC TNM Post Therapy Path (yc) T Suffix	1033	2021 - present
AJCC TNM Clin N Suffix	1034	2021 - present
AJCC TNM Path N Suffix	1035	2021 - present
AJCC TNM Post Therapy Path (yc) N Suffix	1036	2021 –present
AJCC TNM Post Therapy Clin (yc) T	1062	2021 - present
AJCC TNM Post Therapy Clin (yc) T Suffix	1063	2021 - present
AJCC TNM Post Therapy Clin (yc) N	1064	2021 - present
AJCC TNM Post Therapy Clin (yc) N Suffix	1065	2021 - present
AJCC TNM Post Therapy Clin (yc) M	1066	2021 - present
Spread Through Air Spaces (STAS)	1176	2026

Residual Cancer Burden (RCB)	1178	2026
Residual Cancer Burden Class	1179	2026
Phase I Radiation External Beam Planning Tech	1502	2022 - present
Phase II Radiation External Beam Planning Tech	1512	2022 - present
Phase III Radiation External Beam Planning Tech	1522	2022 - present
ALK Rearrangement	3938	2022 - present
Anemia	3811	2022 - present
B symptoms	3812	2022 - present
Behavior 2001 and forward	523	2001 - present
RX Date - Systemic	3230	2004 - 2010 2022 - present
Adenoid Cystic Basaloid Pattern	3803	2022 - present
Birth Surname	2232	2021 - present
Birthplace-Country	254	2013 -present
Birthplace-State	252	2013 - present
AFP Post-Orchiectomy Lab Value	3805	2022 - present
BRAF Mutational Analysis	3940	2022 - present
Brain Molecular Markers	3816	2018 – present
Brain Primary Tumor Location	3964	2024 - present
Breslow Tumor Thickness	3817	2018 – present
CA 19-9 PreTX Lab Value	3942	2022 - present
CA-125 Pretreatment Interpretation	3818	2022 - present
Cancer Status	1770	2022 - present
CEA Pretreatment Interpretation	3819	2022 - present
CEA Pretreatment Lab Value	3820	2022 - present
Chemotherapy Code	1390	1995 - present
Chromosome 16q: Loss of Heterozygosity	1189	2025 - present
Chromosome 19q: Loss of Heterozygosity (LOH)	3802	2022 - present
Chromosome 1p: Loss of Heterozygosity (LOH)	3801	2022 - present
Chromosome 1q Status	1190	2025 - present
Circumferential Resection Margin (CRM)	3823	2022 - present
Class of Case	610	1998 - present
AFP Post-Orchiectomy Range	3806	2022 - present
CoC Accredited Flag	2152	2018 - present
AFP Pre-Orchiectomy Lab Value	3807	2022 - present

AFP Pre-Orchiectomy Range	3808	2022 - present
Current Address - Country	1832	2022 - present
Current Address - State	1820	2022 - present
Current Address - Zip Code	1830	2022 - present
Current Address City	1810	2022 - present
Current Address Number and Street	2350	2022 - present
Current Address Supplemental	2355	2022 - present
Date Abstracted	2090	1995 - present
Date Chemotherapy Started	1220	2010 - present
Date Hormone Therapy Started	1230	2010 - present
Date Immunotherapy (BRM) Started	1240	2010 - present
Date of Admission/First Contact	580	1995 - present
Date of Birth	240	1995 - present
Date of Initial Diagnosis	390	1995 - present
Date of Initial Treatment	1260	2010 - present
Date of Last Cancer (Tumor) Status	1772	2022 - present
Date of Last Followup or Death (Contact)	1750	1995 - present
Date of Sentinal Lymph Node Biopsy	832	2022 - present
Date Other Treatment Started	1250	1995 - present
AFP Pretreatment Interpretation	3809	2022 - present
Derived Pediatric M	1144	2025 - present
Derived Pediatric N	1143	2025 - present
Derived Pediatric Stage Group	1145	2025 - present
Derived Pediatric T	1142	2025 - present
Diagnostic Confirmation	490	1995 - present
EGFR Mutational Analysis	3939	2022 - present
EOD Metastases	776	2022 - present
EOD Primary Tumor	772	2022 - present
EOD Prostate Pathologic Extension	3919	2022 - present
EOD Regional Nodes	774	2022 - present
Esophagus and EGJ Tumor Epicenter	3829	2022 - present
AFP Pretreatment Lab Value	3810	2022 - present
Estrogen Receptor Summary	3827	2018 – present
EWSR1-FLI1 fusion	1191	2025 - present
Bilirubin Pretreatment Total Lab Value	3813	2022 - present
Bilirubin Pretreatment Unit of Measure	3814	2022 - present
Bone Invasion	3815	2022 - present
Creatinine Pretreatment Lab Value	3824	2022 - present
Creatinine Pretreatment Unit of Measure	3825	2022 - present
Final DX Hist/Beh/Grade	2590	1995 - present

Final DX Primary Site and Laterality	2580	1995 - present
FIPS County Code at DX	90	1995 - present
First Name	2240	1995 - present
Follow Up Source	1791	1995 - present
Follow Up Source (Derived)	1790	2009 - present
FOXO1 Gene Rearrangements	1193	2025 - present
Gestational Trophoblastic Prognostic Scoring Index	3837	2022 - present
Gleason Patterns Clinical	3838	2021 - present
Gleason Patterns Pathological	3839	2021 - present
Gleason Score Clinical	3840	2021 - present
Gleason Score Pathological	3841	2021 - present
Gleason Tertiary Pattern	3842	2021 - present
Grade Clinical	3843	2018 – present
Grade Pathological	3844	2018 - present
Grade Post Therapy Clinical (yc)	1068	2021- present
Grade Post Therapy Path (yp)	3845	2021 - present
Estrogen Receptor Percent Positive or Range	3826	2022 - present
Extranodal Extension Clin (non-Head and Neck)	3830	2022 - present
Extranodal Extension Head and Neck Clinical	3831	2022 - present
Extranodal Extension Head and Neck Pathological	3832	2022 - present
HER2 Overall Summary	3855	2018 – present
Heritable Trait	3856	2022 - present
High Risk Cytogenetics	3857	2022 - present
Extranodal Extension Path (non-Head and Neck)	3833	2022 - present
Histologic Subtype	3960	2023- present
Histologic Type ICD-O-3 2001 and forward	522	2001 - present
Hormone Code	1400	1995 - present
Immunotherapy (BRM) Code	1410	1995 - present
FIGO Stage	3836	2022 - present
Intl Neuroblastoma Path Prog Class (INPC)	1187	2025 - present
Intl Neuroblastoma Risk Grp Stage Sys (INRGSS)	1185	2025 - present
hCG Post-Orchiectomy Lab Value	3846	2022 - present
hCG Post-Orchiectomy Range	3847	2022 - present

IRSS Stage for Eye-2	1188	2025 - present
JAK2	3862	2022 - present
hCG Pre-Orchiectomy Lab Value	3848	2022 - present
hCG Pre-Orchiectomy Range	3849	2022 - present
KRAS	3866	2022 - present
Last Name	2230	1995 - present
Laterality	410	1995 - present
LDH Lab Value	3932	2018 – present
LDH Level	3869	2022 - present
High Risk Histologic Features	3858	2022 - present
International Normalized Ratio Prothrombin Time	3860	2022 - present
Ipsilateral Adrenal Gland Involvement	3861	2022 - present
Ki-67	3863	2022 - present
Invasion Beyond Capsule	3864	2022 - present
KIT Gene Immunohistochemistry	3865	2022 - present
LDH Post-Orchiectomy Range	3867	2022 - present
LDH Pre-Orchiectomy Range	3868	2022 - present
LDH Upper Limits of Normal	3870	2022 - present
LN Assessment Method Femoral- Inguinal	3871	2022 - present
LN Assessment Method Para-Aortic	3872	2022 - present
LN Assessment Method Pelvic	3873	2022 - present
LN Distant Assessment Method	3874	2022 - present
LN Positive Axillary Level I-II	3882	2022 - present
LN Distant: Mediastinal, Scalene	3875	2022 - present
LN Head and Neck Levels I-III	3876	2022 - present
LN Head and Neck Levels IV-V	3877	2022 - present
LN Head and Neck Levels VI-VII	3878	2022 - present
Lymphocytosis	3885	2022 - present
Lymphovascular Invasion (testis and penis only)	1182	2011 - present
LN Head and Neck Other	3879	2022 - present
LN Isolated Tumor Cells (ITC)	3880	2022 - present
Marital Status at Dx	150	2022 - present
Measured Basal Diameter	3887	2022 - present
Measured Thickness	3888	2022 - present
Medical Record Number	2300	1995 - present
Medicare Beneficiary Identifier	2315	2021 - present
Methylation of O6-Methylguanine- Methyltransferase	3889	2022 - present
Mets at Diagnosis – Distant LNs	1114	2022 - present

Mets at Diagnosis – Liver	1115	2022 - present
Mets at Diagnosis-Bone	1112	2022 - present
Mets at Diagnosis-Brain	1113	2022 - present
Mets at Diagnosis-Lung	1116	2022 - present
Mets at Diagnosis-Other	1117	2022 - present
Microsatellite Instability (MSI)	3890	2018 - present
Middle Name	2250	1995 - present
LN Size	3883	2022 - present
Mitotic Rate Melanoma	3893	2022 - present
NAACCR Record Version	50	2003 - present
Name--Suffix	2270	2022 - present
Major Vein Involvement	3886	2022 - present
Neoadjuvant Therapy	1632	2022 - present
Neoadjuvant Therapy-Clinical Response	1633	2022 - present
Neoadjuvant Therapy-Treatment Effect	1634	2022 - present
n-MYC Amplification	1186	2025 - present
NPI Reporting Facility (Derived)	545	2009 - present
NRAS Mutational Analysis	3941	2022 - present
Number of Cores Examined	3897	2022 - present
Number of Cores Positive	3898	2022 - present
Mitotic Count Uveal Melanoma	3892	2022 - present
NCCN International Prognostic Index (IPI)	3896	2022 - present
Number of Phases of Rad Treatment to this Volume	1532	2022 - present
Number of Examined Para-Aortic Node	3899	2022 - present
Number of Examined Pelvic Nodes	3900	2022 - present
Oncotype Dx Recurrence Score-Invasive	3904	2022 - present
Organomegaly	3907	2022 - present
Other Pertinent Information	2680	1995 - present
Other Treatment Code	1420	1995 - present
p16	3956	2022 - present
Patient Name Alias	2280	1995 - 2002 2006 - present
PD-L1	1174	2025 - present
Pediatric ID	1132	2025 - present
Pediatric ID Version Current	1133	2025 - present
Pediatric ID Version Original	1134	2025 - present

Pediatric Mets	1138	2025 - present
Pediatric Primary Tumor	1136	2025 - present
Pediatric Regional Nodes	1137	2025 - present
Perineural Invasion	3909	2022 - present
Peripheral Blood Involvement	3910	2022 - present
Peritoneal Cytology	3911	2022 - present
Phase I Dose per Fraction	1501	2022 - present
Phase I Number of Fractions	1503	2022 - present
Number of Positive Para-Aortic Nodes	3901	2022 - present
Phase I Radiation Primary Treatment Volume	1504	2022 - present
Phase I Radiation to Draining Lymph Nodes	1505	2022 - present
Phase I Radiation Treatment Modality	1506	2018 - present
Phase I Total Dose	1507	2022 - present
Phase II Dose per Fraction	1511	2022 - present
Phase II Number of Fractions	1513	2022 - present
Number of Positive Pelvic Nodes	3902	2022 - present
Phase II Radiation Primary Treatment Volume	1514	2022 - present
Phase II Radiation to Draining Lymph Nodes	1515	2022 - present
Phase II Radiation Treatment Modality	1516	2022 - present
Phase II Total Dose	1517	2022 - present
Phase III Dose per Fraction	1521	2022 - present
Phase III Number of Fractions	1523	2022 - present
Progesterone Receptor Percent Positive or Range	3914	2022 - present
Phase III Radiation Primary Treatment Volume	1524	2022 - present
Phase III Radiation to Draining Lymph Nodes	1525	2022 - present
Phase III Radiation Treatment Modality	1526	2022 - present
Phase III Total Dose	1527	2022 - present
Physician Follow Up	2470	2006 - present
Place of Death-Country	1944	2013 - present
Place of Death-State	1942	2013 - present
Pleural Effusion	3913	2022 - present
Post Transplant Lymphoproliferative Disorder-PTLD	1172	2025 - present
Pretext Clinical Staging	1192	2025 - present

Primary Payer at DX	630	2007 - present
Primary Site	400	1995 - present
Profound Immune Suppression	3918	2022 - present
Residual Tumor Volume Post Cytoreduction	3921	2022 - present
Progesterone Receptor Summary	3915	2018 - present
PSA (Prostatic Specific Antigen) Lab Value	3920	2018 - present
Race 1	160	1995 - present
Race 2	161	2001 - present
Race 3	162	2001 - present
Race 4	163	2001 - present
Race 5	164	2001 - present
Radiation Treatment Discontinued Early	1531	2022 - present
Reason for no Radiation	1430	1998 - present
Reason for No Surgery	1340	1998 - 2002 - present 2026
Recurrence Date--1st	1860	2022 - present
Recurrence Type--1st	1880	2022 - present
Regional Nodes Examined	830	1998 - present
Regional Nodes Positive	820	1998 - present
Registry/Accession Number	550	1995 - present
Reporting Facility	540	1995 - present
Response to Neoadjuvant Therapy	3922	2022 - present
Separate Tumor Nodules	3929	2022 - present
Tumor Deposits	3934	2022 - present
Visceral and Parietal Pleural Invasion	3937	2022 - present
RX - Summary Treatment Status	1285	2010 - present
Macroscopic Evaluation of the Mesorectum	3950	2022 - present
RX Date Mst Defn Srg	3170	2015 - present
Rx Date Radiation	1210	1995 - present
RX Date Surgery	1200	1995 - present
RX Hosp—BRM (Immunotherapy)	720	2022 - present
RX Hosp--Chemo	700	2022 - present
RX Hosp--Hormone	710	2022 - present
RX Hosp--Other	730	2022 - present
RX Hosp--Rcon Breast	751	2024 - present
RX Hosp—Scope of Reg LN Sur	672	2022 - present

RX Hosp—Surg Oth Reg/Dis	674	2022 - present
RX Hosp—Surg Prim Site 2023	671	2023 - present
RX Summary - Scope of Reg LN Surgery	1292	2001 - present
RX Summary - Surgery Other/Dist RX Code	1294	1998 - present
RX Summary - Surgery/Radiation Sequence	1380	2004 - present
RX Summary - Systemic/Surgery Sequence	1639	2006 - present
RX Summary Transplant/Endocrine	3250	2003 - present
RX Summ—Recon Breast	1335	2024 - present
RX Summ—Surg Prim Site 2023	1291	2023 - present
RX Text - Chemotherapy	2640	2004 - present
RX Text - Hormone	2650	2004 - present
RX Text – Immunotherapy (BRM)	2660	2004 - present
RX Text - Other	2670	2004 - present
RX Text - Radiation	2620, 2630	2004 - present
RX Text Surgery	2610	2004 - present
S Category Clinical	3923	2022 - present
S Category Pathological	3924	2022 - present
Sarcomatoid Features	3925	2022 - present
Schema Discriminator 1	3926	2018 - present
Schema Discriminator 2	3927	2018 - present
Schema Discriminator 3	3928	2022 - present
Schema ID	3800	2018 - present
Secondary Diagnosis 1	3780	2023 - present
Secondary Diagnosis 10	3798	2023 - present
Secondary Diagnosis 2	3782	2023 - present
Secondary Diagnosis 3	3784	2023 - present
Secondary Diagnosis 4	3786	2023 - present
Secondary Diagnosis 5	3788	2023 - present
Secondary Diagnosis 6	3790	2023 - present
Secondary Diagnosis 7	3792	2023 - present
Secondary Diagnosis 8	3794	2023 - present
Secondary Diagnosis 9	3796	2023 - present
SEER Site Specific Factor 1	3700	2022 - present
Sentinel Lymph Nodes Examined	834	2022 - present
Sentinel Lymph Nodes Positive	835	2022 - present
LN Status Pelvic	3957	2022 - present
Sequence Number Central	380	1995 - present
Sequence Number Hospital	560	1995 - present

Serum Albumin Pretreatment Level	3930	2022 - present
Serum Beta-2 Microglobulin Pretreatment Level	3931	2022 - present
Sex Assigned at Birth	225	2026
Social Security Number	2320	1995 - present
Spanish/Hispanic Origin	190	1995 - present
LN Status Para-Aortic	3958	2022 - present
Summary Stage 2018	764	2018 - present
Summary Stage Documentation	2520-2570, 2600	1995 - present
Surgical Margins of Primary Site	1320	2022 - present
Telephone	2360	2022 - present
Text Usual Industry	320	2010 - present
Text Usual Occupation	310	2010 - present
Thrombocytopenia	3933	2022 - present
TNM Edition Number	1060	2015 - present
Tobacco Use Smoking Status	344	2022 - present
Toronto M	1148	2025 - present
Toronto N	1147	2025 - present
Toronto Stage Group	1149	2025 - present
Toronto T	1146	2025 - present
Toronto Version Number	1135	2025 - present
Total Dose	1533	2022 - present
LN Status Femoral-Inguinal	3959	2022 - present
Tumor Record Number	60	2026
Tumor Size Summary	756	2016 - present
Type of Reporting Source	500	1995 - present
Ulceration	3936	2022 - present
Underlying Cause of Death	1910	2022 - present
Clinical Margin Width	3961	2023 - present
Vital Status	1760	1998 - present
White Blood Cell Count	1184	2025 - present

[illegible]

CoC	
CoC	
CoC	
CoC	
CoC	
CoC	
CoC	
CoC	
CoC	
CoC	

[illegible]

Derived	
Derived	
CoC	
CoC	
CoC	
CoC	
CoC	
CoC	
CoC	
CoC	

[illegible]

CoC	
Current version	
CoC	
Derived	
CoC	
CoC	
CoC	
CoC	
Derived	
Derived	
Derived	

[illegible]

[illegible]

[illegible]

CoC	
Derived	
Derived	
Derived	
Derived	
Derived	
CoC	
Derived	
Linkage	
CoC	